Angiotensin II, hypertension and angiotensin II receptor antagonism: Roles in the behavioural and brain pathology of a mouse model of Alzheimer's disease

Journal of Cerebral Blood Flow and Metabolism

Volumn 37, Issue 7, 2017, Pages 2396-2413

  Wiesmann, Maximilian ^a   Roelofs, Monica ^a   van der Lugt, Robert ^a   Heerschap, Arend ^a   Kiliaan, Amanda J ^a   Claassen, Jurgen AHR ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer s; brain imaging; cerebral blood flow; cognitive impairment; hypertension

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; EPROSARTAN; AMYLOID BETA PROTEIN; EPROSARTAN MESYLATE DIHYDRATE; IMIDAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN CORTEX; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFUSION TENSOR IMAGING; EXPERIMENTAL HYPERTENSION; FUNCTIONAL CONNECTIVITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IMPLANTATION; MALE; MICROPUMP IMPLANTATION; MORRIS WATER MAZE TEST; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RISK FACTOR; SPATIAL LEARNING; SYSTOLIC BLOOD PRESSURE; THALAMUS; ANIMAL; ANIMAL BEHAVIOR; BLOOD PRESSURE; BRAIN; BRAIN CIRCULATION; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENETICS; MAZE TEST; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; VASCULARIZATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; BEHAVIOR, ANIMAL; BLOOD PRESSURE; BRAIN; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; HYPERTENSION; IMIDAZOLES; MAZE LEARNING; MICE, TRANSGENIC; SPATIAL LEARNING; THIOPHENES;

EID: 85021144015     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X16667364     Document Type: Article

References (117)

1. Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement 2010; 6: 98–103.
2. Arevalo-Rodriguez I, Pedraza OL, Rodríguez A. Alzheimer’s disease dementia guidelines for diagnostic testing: a systematic review. Am J Alzheimers Dis Other Demen 2013; 28: 111–119.
3. Morris JC. The nosology of dementia. Neurol Clin 2000; 18: 773–788.
4. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 2003; 34: 335–337.
5. Kilander L, Andrén B, Nyman H. Atrial fibrillation is an independent determinant of low cognitive function. Stroke 1998; 29: 1816–1820.
6. Kivipelto M, Helkala E-L, Laakso MP. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447–1451.
7. Launer LJ, Ross GW, Petrovitch H. Midlife blood pressure and dementia: the Honolulu–Asia aging study. Neurobiol Aging 2000; 21: 49–55.
8. Nagata KEN, Sato M, Satoh Y. Hemodynamic aspects of Alzheimer’s disease. Ann N Y Acad Sci 2002; 977: 391–402.
9. Ott A, Stolk RP, Hofman A. Association of diabetes mellitus and dementia: the Rotterdam study. Diabetologia 1996; 39: 1392–1397.
10. Posner HB, Tang M-X, Luchsinger J. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2000; 58: 1175–1181.
11. Ringman JM, Sachs MC, Zhou Y. Clinical predictors of severe cerebral amyloid angiopathy and influence of apoe genotype in persons with pathologically verified Alzheimer disease. JAMA Neurol 2014; 71: 878–883.
12. Wiesmann M, Kiliaan AJ, Claassen JA. Vascular aspects of cognitive impairment and dementia. J Cereb Blood Flow Metab 2013; 33: 1696–1706.
13. Skoog I, Nilsson L, Persson G. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–1145.
14. Hofman A, Ott A, Breteler M. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet 1997; 349: 151–154.
15. Kehoe PG, Wilcock GK. Is inhibition of the renin–angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol 2007; 6: 373–378.
16. Brasier AR, Recinos A, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257–1266.
17. Kehoe PG, Miners S, Love S. Angiotensins in Alzheimer’s disease–friend or foe? Trends Neurosci 2009; 32: 619–628.
18. Reckelhoff JF and Romero JC. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2003; 284: R893–R912
19. Bloch S, Obari D, Girouard H. Angiotensin and neurovascular coupling: beyond hypertension. Microcirculation 2015; 22: 159–167.
20. Saavedra JM. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol 2005; 25: 485–512.
21. Marchesi C, Paradis P, Schiffrin EL. Role of the renin–angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008; 29: 367–374.
22. Gorelick PB, Scuteri A, Black SE. Vascular contributions to cognitive impairment and dementia a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 2672–2713.
23. Kurinami H, Shimamura M, Sato N. Do angiotensin receptor blockers protect against Alzheimer’s disease? Drugs Aging 2013; 30: 1–6.
24. Capone C, Faraco G, Park L. The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. Am J Physiol Heart Circ Physiol 2011; 300: H397–H407.
25. Ruitenberg A, den Heijer T, Bakker SLM. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam study. Ann Neurol 2005; 57: 789–794.
26. Niwa K, Porter VA, Kazama K. Aβ-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 2001; 281: H2417–H2424.
27. Prohovnik I, Mayeux R, Sackeim HA. Cerebral perfusion as a diagnostic marker of early Alzheimer’s disease. Neurology 1988; 38: 931.
28. Duara R, Grady C, Haxby J. Positron emission tomography in Alzheimer’s disease. Neurology 1986; 36: 879.
29. Jagust WJ, Seab JP, Huesman RH. Diminished glucose transport in Alzheimer’s disease: dynamic PET studies. J Cereb Blood Flow Metab 1991; 11: 323–330.
30. Choeiri C, Staines W, Messier C. Immunohistochemical localization and quantification of glucose transporters in the mouse brain. Neuroscience 2002; 111: 19–34.
31. Simpson IA, Chundu KR, Davies-Hill T. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer’s disease. Ann Neurol 1994; 35: 546–551.
32. Kalaria RN, Harik SI. Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. J Neurochem 1989; 53: 1083–1088.
33. Horwood N, Davies DC. Immunolabelling of hippocampal microvessel glucose transporter protein is reduced in Alzheimer’s disease. Virchows Arch 1994; 425: 69–72.
34. Akiyama H, Barger S, Barnum S. Inflammation and Alzheimer’s disease. Neurobiol Aging 2000; 21: 383–421.
35. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007; 7: 161–167.
36. Zotova E, Nicoll JA, Kalaria R. Inflammation in Alzheimer’s disease: relevance to pathogenesis and therapy. Alzheimers Res Ther 2010; 2: 1–9.
37. Imai Y, Ibata I, Ito D. A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem Biophys Res Commun 1996; 224: 855–862.
38. Ahmed Z, Shaw G, Sharma VP. Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J Histochem Cytochem 2007; 55: 687–700.
39. Streit WJ, Braak H, Xue Q-S. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease. Acta Neuropathol 2009; 118: 475–485.
40. Yamada K, Uchida S, Takahashi S. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer’s disease. Brain Res 2010; 1352: 176–186.
41. Muller M, van der Graaf Y, Visseren FL. Hypertension and longitudinal changes in cerebral blood flow: the SMART-MR study. Ann Neurol 2012; 71: 825–833.
42. Tsukuda K, Mogi M, Iwanami J. Cognitive deficit in amyloid-β–injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-γ activation. Hypertension 2009; 54: 782–787.
43. Shlyakhto E. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10 000 patients and review of the literature. Curr Med Res Opin 2007; 23: S13–SS8.
44. Haag M, Hofman A, Koudstaal P. Duration of antihypertensive drug use and risk of dementia A prospective cohort study. Neurology 2009; 72: 1727–1734.
45. Keeman J, Mazel J and Zitman F. Het medisch jaar 2008/2009. Houten, The Netherlands: Bohn Stafleu van Loghum, 2009
46. Davies NM, Kehoe PG, Ben-Shlomo Y. Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias. J Alzheimers Dis 2011; 26: 699–708.
47. Marpillat NL, Macquin-Mavier I, Tropeano A-I. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens 2013; 31: 1073–1082.
48. Zimmerman MC, Lazartigues E, Sharma RV. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res 2004; 95: 210–216.
49. Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer’s disease by spin-labeled magnetic resonance imaging. Ann Neurol 2000; 47: 93–100.
50. Sandson TA, O’Connor M, Sperling RA. Noninvasive perfusion MRI in Alzheimer’s disease: a preliminary report. Neurology 1996; 47: 1339–1342.
51. Asllani I, Habeck C, Scarmeas N. Multivariate and univariate analysis of continuous arterial spin labeling perfusion MRI in Alzheimer’s disease. J Cereb Blood Flow Metab 2008; 28: 725–736.
52. Stebbins GT, Murphy CM. Diffusion tensor imaging in Alzheimer’s disease and mild cognitive impairment. Behav Neurol 2009; 21: 39–49.
53. Salat DH, Tuch DS, van der Kouwe AJW. White matter pathology isolates the hippocampal formation in Alzheimer’s disease. Neurobiol Aging 2010; 31: 244–256.
54. Bozzali M, Falini A, Franceschi M. White matter damage in Alzheimer’s disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2002; 72: 742–746.
55. Stahl R, Dietrich O, Teipel SJ. White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology 2007; 243: 483–492.
56. Head D, Buckner RL, Shimony JS. Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from diffusion tensor imaging. Cereb Cortex 2004; 14: 410–423.
57. Fellgiebel A, Wille P, Müller MJ. Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study. Dement Geriatr Cogn Disord 2004; 18: 101–108.
58. Bozzali M, Franceschi M, Falini A. Quantification of tissue damage in AD using diffusion tensor and magnetization transfer MRI. Neurology 2001; 57: 1135–1137.
59. Kavcic V, Ni H, Zhu T. White matter integrity linked to functional impairments in aging and early Alzheimer’s disease. Alzheimers Dement 2008; 4: 381–389.
60. Jankowsky JL, Fadale DJ, Anderson J. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase. Hum Mol Genet 2004; 13: 159–170.
61. Jankowsky JL, Slunt HH, Ratovitski T. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 2001; 17: 157–165.
62. Kilkenny C, Browne WJ, Cuthill IC. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010; 8: e1000412.
63. Wiesmann M, Capone C, Zerbi V. Hypertension impairs cerebral blood flow in a mouse model for Alzheimer’s disease. Curr Alzheimer Res 2015; 12: 914–922.
64. Janssen CIF, Zerbi V, Mutsaers MPC. Impact of dietary n-3 polyunsaturated fatty acids on cognition, motor skills and hippocampal neurogenesis in developing C57BL/6J mice. J Nutr Biochem 2015; 26: 24–35.
65. Wiesmann M, Zerbi V, Jansen D. A dietary treatment improves cerebral blood flow and brain connectivity in aging apoE4 mice. Neural Plast 2016; 2016: 15.
66. Zerbi V, Jansen D, Wiesmann M. Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer’s disease. Neurobiol Aging 2014; 35: 600–613.
67. Kim SG. Quantification of relative cerebral blood flow change by flow-sensitive alternating inversion recovery (FAIR) technique: Application to functional mapping. Magn Reson Med 1995; 34: 293–301.
68. Kwong KK, Chesler DA, Weisskoff RM. MR perfusion studies with T1-weighted echo planar imaging. Magn Reson Med 1995; 34: 878–887.
69. Paxinos G, Franklin KB. The mouse brain in stereotaxic coordinates/George Paxinos, Keith Franklin, London: Academic, 2004.
70. Harsan LA, Paul D, Schnell S. In vivo diffusion tensor magnetic resonance imaging and fiber tracking of the mouse brain. NMR Biomed 2010; 23: 884–896.
71. Jansen D, Zerbi V, Janssen CI. Impact of a multi-nutrient diet on cognition, brain metabolism, hemodynamics, and plasticity in apoE4 carrier and apoE knockout mice. Brain Struct Funct 2014; 219: 1841–1868.
72. Le Bihan D, Mangin J-F, Poupon C. Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 2001; 13: 534–546.
73. Alexander AL, Hurley SA, Samsonov AA. Characterization of cerebral white matter properties using quantitative magnetic resonance imaging stains. Brain Connect 2011; 1: 423–446.
74. Feldman HM, Yeatman JD, Lee ES. Diffusion tensor imaging: a review for pediatric researchers and clinicians. J Dev Behav Pediatr 2010; 31: 346–356.
75. Li R, Wu X, Chen K. Alterations of directional connectivity among resting-state networks in Alzheimer disease. AJNR Am J Neuroradiol 2013; 34: 340–345.
76. Hooijmans CR, Graven C, Dederen PJ. Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice. Brain Res 2007; 1181: 93–103.
77. Toth P, Tucsek Z, Sosnowska D. Age-related autoregulatory dysfunction and cerebromicrovascular injury in mice with angiotensin II-induced hypertension. J Cereb Blood Flow Metab 2013; 33: 1732–1742.
78. Allen G, Barnard H, McColl R. Reduced hippocampal functional connectivity in Alzheimer disease. Arch Neurol 2007; 64: 1482–1487.
79. Supekar K, Menon V, Rubin D. Network analysis of intrinsic functional brain connectivity in Alzheimer’s disease. PLoS Comput Biol 2008; 4: e1000100.
80. Wang L, Zang Y, He Y. Changes in hippocampal connectivity in the early stages of Alzheimer’s disease: evidence from resting state fMRI. Neuroimage 2006; 31: 496–504.
81. Grandjean J, Schroeter A, He P. Early alterations in functional connectivity and white matter structure in a transgenic mouse model of cerebral amyloidosis. J Neurosci 2014; 34: 13780–13789.
82. Vincent JL, Patel GH, Fox MD. Intrinsic functional architecture in the anaesthetized monkey brain. Nature 2007; 447: 83–86.
83. Lu H, Zuo Y, Gu H. Synchronized delta oscillations correlate with the resting-state functional MRI signal. Proc Natl Acad Sci USA 2007; 104: 18265–18269.
84. Pan W-J, Billings JCW, Grooms JK. Considerations for resting state functional MRI and functional connectivity studies in rodents. Front Neurosci 2015; 9: 269.
85. Zhou IY, Liang Y-X, Chan RW. Brain resting-state functional MRI connectivity: morphological foundation and plasticity. Neuroimage 2014; 84: 1–10.
86. Liang Z, King J, Zhang N. Intrinsic organization of the anesthetized brain. J Neurosci 2012; 32: 10183–10191.
87. Jonckers E, Van Audekerke J, De Visscher G. Functional connectivity fMRI of the rodent brain: comparison of functional connectivity networks in rat and mouse. PLoS ONE 2011; 6: e18876.
88. Guilfoyle DN, Gerum SV, Sanchez JL. Functional connectivity fMRI in mouse brain at 7 T using isoflurane. J Neurosci Meth 2013; 214: 144–148.
89. Zerbi V, Wiesmann M, Emmerzaal TL. Resting-state functional connectivity changes in aging apoE4 and apoE-KO mice. J Neurosci 2014; 34: 13963–13975.
90. Johnson NA, Jahng G-H, Weiner MW. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005; 234: 851–859.
91. Sun X, He G, Qing H. Hypoxia facilitates Alzheimer’s disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA 2006; 103: 18727–18732.
92. Kawada N, Imai E, Karber A. A mouse model of angiotensin II slow pressor response: role of oxidative stress. J Am Soc Nephrol 2002; 13: 2860–2868.
93. Qi G, Jia L, Li Y. Angiotensin II infusion–induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. Cardiovasc Toxicol 2011; 11: 157–167.
94. Edgley AJ, Kett MM, Anderson WP. ‘Slow Pressor’ hypertension from low-dose chronic angiotensin II infusion. Clin Exp Pharmacol Physiol 2001; 28: 1035–1039.
95. Mantini D, Perrucci MG, Del Gratta C. Electrophysiological signatures of resting state networks in the human brain. Proc Natl Acad Sci USA 2007; 104: 13170–13175.
96. Son SJ, Kim J, Lee E. Effect of hypertension on the resting-state functional connectivity in patients with Alzheimer’s disease (AD). Arch Gerontol Geriatr 2015; 60: 210–216.
97. Haley AP, Gunstad J, Cohen RA. Neural correlates of visuospatial working memory in healthy young adults at risk for hypertension. Brain Imaging Behav 2008; 2: 192–199.
98. Sharma B, Singh N. Defensive effect of natrium diethyldithiocarbamate trihydrate (NDDCT) and lisinopril in DOCA–salt hypertension-induced vascular dementia in rats. Psychopharmacology 2012; 223: 307–317.
99. Li X, Liang Y, Chen Y. Disrupted frontoparietal network mediates white matter structure dysfunction associated with cognitive decline in hypertension patients. J Neurosci 2015; 35: 10015–10024.
100. Brosius FC, III Liu Y, Nguyen N. Persistent myocardial ischemia increases GLUT1 glucose transporter expression in both ischemic and non-ischemic heart regions. J Mol Cell Cardiol 1997; 29: 1675–1685.
101. Feldhaus LM, Liedtke AJ. mRNA expression of glycolytic enzymes and glucose transporter proteins in ischemic myocardium with and without reperfusion. J Mol Cell Cardiol 1998; 30: 2475–2485.
102. McCall AL, Van Bueren AM, Nipper V. Forebrain ischemia increases glut1 protein in brain microvessels and parenchyma. J Cereb Blood Flow Metab 1996; 16: 69–76.
103. Urabe T, Hattori N, Nagamatsu S. Expression of glucose transporters in rat brain following transient focal ischemic injury. J Neurochem 1996; 67: 265–271.
104. Gerhart DZ, Leino RL, Taylor WE. GLUT1 and GLUT3 gene expression in gerbil brain following brief ischemia: an in situ hybridization study. Brain Res Mol Brain Res 1994; 25: 313–322.
105. Cifuentes D, Poittevin M, Dere E. Hypertension accelerates the progression of Alzheimer-like pathology in a mouse model of the disease. Hypertension 2015; 65: 218–224.
106. Derosa G, Ragonesi PD, Mugellini A. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27: 457–464.
107. Tryambake D, He J, Firbank MJ. Intensive blood pressure lowering increases cerebral blood flow in older subjects with hypertension. Hypertension 2013; 61: 1309–1315.
108. Gons RAR, de Laat KF, van Norden AGW. Hypertension and cerebral diffusion tensor imaging in small vessel disease. Stroke 2010; 41: 2801–2806.
109. de Leeuw FE, de Groot JC, Oudkerk M. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 2002; 125: 765–772.
110. Füchtemeier M, Brinckmann MP, Foddis M. Vascular change and opposing effects of the angiotensin type 2 receptor in a mouse model of vascular cognitive impairment. J Cereb Blood Flow Metab 2015; 35: 476–484.
111. Henriksen EJ, Jacob S, Kinnick TR. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 38: 884–890.
112. Hampel H, Blennow K, Shaw LM. Total and phosphorylated tau protein as biological markers of Alzheimer’s disease. Exp Gerontol 2010; 45: 30–40.
113. Glodzik L, Rusinek H, Pirraglia E. Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly. Neurobiol Aging 2014; 35: 64–71.
114. Vogels RLC, Scheltens P, Schroeder-Tanka JM. Cognitive impairment in heart failure: A systematic review of the literature. Eur J Heart Fail 2007; 9: 440–449.
115. Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease. Brain 2015; 138: 2814–2833.
116. Jack CR, Jr Therneau TM, Wiste HJ. Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurol 2015; 15: 56–64.
117. Jack CR, Jr Wiste HJ, Weigand SD. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study. Lancet Neurol 2014; 13: 997–1005.